Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder.

ABSTRACT:

Importance

In 2017, the US Food and Drug Administration (FDA) approved a monthly injectable form of buprenorphine, extended-release buprenorphine; published data show that extended-release buprenorphine is effective compared with no treatment, but its current cost is higher and current retention is lower than that of transmucosal buprenorphine. Preliminary research suggests that extended-release buprenorphine may be an important addition to treatment options, but the cost-effectiveness of extended-release buprenorphine compared with transmucosal buprenorphine remains unclear.

Objective

To evaluate the cost-effectiveness of extended-release buprenorphine compared with transmucosal buprenorphine.

Design, setting, and participants

This economic evaluation used a state tr

SUBMITTER: Flam-Ross JM 

PROVIDER: S-EPMC10500382 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature